CTOs on the Move

Alladapt

www.alladapt.com

 
We are dedicated to developing and commercializing effective and broadly applicable interventions for food allergy. Food allergy is a disease of the immune system that is triggered by an exceptionally broad range of commonly allergenic foods such as cow’s milk, eggs, tree nuts, peanuts, shellfish and even sesame. In a perfect world, the human immune system would adapt to all foods. However, in tens of millions of people, the immune system wrongly recognizes some food proteins as harmful and does not adapt. We envision a world where, with help from oral immunotherapy, the immune system can adapt to nearly all food ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.alladapt.com
  • 405 El Camino Real # 611
    Menlo Park, CA USA 94025
  • Phone: 650.420.3900

Executives

Name Title Contact Details
Michael Holfinger
Chief Technical Officer Profile

Funding

Alladapt raised $60M on 02/20/2020
Alladapt raised $119M on 06/22/2022

Similar Companies

Avidity Biosciences

Avidity Biosciences, Inc.`s mission is to profoundly improve people`s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity`s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity`s advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA.

Kiniciti

Empowering the industry with the resources, expertise, and capital to help accelerate the advancement and adoption of cell and gene therapies.

BioInquire

BioInquire is a Athens, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DMC

DMC is leading the low cost sustainable transformation of multiple product markets.

Medicure

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market.